You are here:

telaprevir (Incivo) Naive

Advice

following a full submission: 

telaprevir (Incivo®) is accepted for use within NHS Scotland. 

Indication under review: in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis) who are treatment-naïve. 

In the pivotal phase III randomised study, addition of telaprevir to current standard therapy in treatment-naïve patients with genotype 1 chronic hepatitis C virus, significantly increased the proportion of patients who achieved a sustained virologic response, even in patients treated for a shorter overall duration using response-guided therapy.

Drug Details

Drug Name: telaprevir (Incivo) Naive
SMC Drug ID: 743/11
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with peginterferon alfa and ribavirin (PR), for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis): who are treatment naive
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 December 2011

Back